{"disease":{"id":"raynaud-s-phenomenon","name":"raynaud s phenomenon"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02202291","title":"Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon","phase":"NA","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04040322","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Civi Biopharma, Inc.","has_results":true},{"nct_id":"NCT03094910","title":"Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT03211325","title":"Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.","phase":"NA","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT04915950","title":"A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Pfizer","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}